CA2129099A1 - Pharmaceutical compositions having good dissolution properties - Google Patents

Pharmaceutical compositions having good dissolution properties

Info

Publication number
CA2129099A1
CA2129099A1 CA002129099A CA2129099A CA2129099A1 CA 2129099 A1 CA2129099 A1 CA 2129099A1 CA 002129099 A CA002129099 A CA 002129099A CA 2129099 A CA2129099 A CA 2129099A CA 2129099 A1 CA2129099 A1 CA 2129099A1
Authority
CA
Canada
Prior art keywords
salt
pharmaceutical composition
ifetroban
weight
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002129099A
Other languages
English (en)
French (fr)
Inventor
Faranak Nikfar
Abu T. M. Serajuddin
Robert L. Jerzewski
Nemichand B. Jain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2129099A1 publication Critical patent/CA2129099A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002129099A 1993-08-02 1994-07-28 Pharmaceutical compositions having good dissolution properties Abandoned CA2129099A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10080293A 1993-08-02 1993-08-02
US100,802 1993-08-02

Publications (1)

Publication Number Publication Date
CA2129099A1 true CA2129099A1 (en) 1995-02-03

Family

ID=22281616

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002129099A Abandoned CA2129099A1 (en) 1993-08-02 1994-07-28 Pharmaceutical compositions having good dissolution properties

Country Status (15)

Country Link
EP (1) EP0638310A1 (en:Method)
JP (1) JPH07145052A (en:Method)
KR (1) KR950005309A (en:Method)
CN (1) CN1118254A (en:Method)
AU (1) AU6878294A (en:Method)
CA (1) CA2129099A1 (en:Method)
CZ (1) CZ181094A3 (en:Method)
FI (1) FI943569L (en:Method)
HU (1) HUT70951A (en:Method)
IL (1) IL110376A (en:Method)
NO (1) NO942854L (en:Method)
NZ (1) NZ264129A (en:Method)
PL (1) PL304508A1 (en:Method)
RU (1) RU94028273A (en:Method)
ZA (1) ZA945672B (en:Method)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0839526A3 (en) 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with fast buccal disintegration or dissolution
EP2263660B1 (en) 1998-05-18 2017-09-27 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
MY151098A (en) 1998-07-28 2014-04-15 Takeda Pharmaceutical Rapidly disintegrable solid preparation
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
JP4698000B2 (ja) * 2000-06-27 2011-06-08 旭化成ケミカルズ株式会社 水易溶性薬物含有錠剤
WO2002072069A1 (en) * 2001-03-12 2002-09-19 Novo Nordisk A/S Novel tablets and capsules and a process for its preparation
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
DE10341414A1 (de) * 2003-09-05 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe
CN100438914C (zh) * 2003-10-15 2008-12-03 富士化学工业株式会社 用于口腔内快速崩解的片剂的组合物
US8349361B2 (en) 2003-10-15 2013-01-08 Fuji Chemical Industry Co., Ltd. Composition for rapid disintegrating tablet in oral cavity
JP3841804B2 (ja) 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
HRP20130148T4 (hr) 2006-08-03 2016-10-07 Horizon Pharma Ag Liječenje reumatske bolesti glukokortikoidima s odgođenim otpuštanjem
MX2009010474A (es) * 2007-03-29 2009-10-19 Daiichi Sankyo Co Ltd Composicion farmaceutica.
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
US12161632B2 (en) 2014-05-16 2024-12-10 Cumberland Pharmaceuticals Inc. Compositions and methods of treating cardiac fibrosis with ifetroban
AU2015258805B2 (en) 2014-05-16 2018-05-10 Cumberland Pharmaceuticals, Inc. Compositions and methods of treating cardiac fibrosis with ifetroban
US20170000771A1 (en) 2015-06-30 2017-01-05 Cumberland Pharmaceuticals, Inc. Thromboxane Receptor Antagonists in AERD/Asthma
JP7653218B2 (ja) 2016-05-05 2025-03-28 アクエスティブ セラピューティクス インコーポレイテッド 送達増強エピネフリン組成物
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
JP7003062B2 (ja) 2016-05-11 2022-01-20 カンバーランド ファーマシューティカルズ，インコーポレーテッド トロンボキサンａ２受容体拮抗薬により筋ジストロフィーを治療する組成物及び方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100889A (en) * 1989-04-03 1992-03-31 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
DD299186A5 (de) * 1990-10-01 1992-04-02 E.R. Squibb U. Sons,Inc.,Us Phenylen-7-oxabicycloheptyl-substituierte heterocycloamid-prostaglandinanaloga

Also Published As

Publication number Publication date
NO942854D0 (en:Method) 1994-08-01
FI943569A7 (fi) 1995-02-03
FI943569L (fi) 1995-02-03
IL110376A (en) 1998-08-16
HUT70951A (en) 1995-11-28
HU9402254D0 (en) 1994-09-28
AU6878294A (en) 1995-02-09
CZ181094A3 (en) 1995-02-15
NO942854L (no) 1995-02-03
RU94028273A (ru) 1996-11-10
KR950005309A (ko) 1995-03-20
CN1118254A (zh) 1996-03-13
NZ264129A (en) 1996-05-28
EP0638310A1 (en) 1995-02-15
PL304508A1 (en) 1995-02-06
JPH07145052A (ja) 1995-06-06
ZA945672B (en) 1995-03-06
FI943569A0 (fi) 1994-07-29
IL110376A0 (en) 1994-10-21

Similar Documents

Publication Publication Date Title
US5506248A (en) Pharmaceutical compositions having good dissolution properties
CA2129099A1 (en) Pharmaceutical compositions having good dissolution properties
KR0179343B1 (ko) 속용성 고형 제제
AU624117B2 (en) Pharmaceutical compositions having good stability
US6174548B1 (en) Omeprazole formulation
EP0477333B1 (en) Pharmaceutical formulations
US5180589A (en) Pravastatin pharmaceuatical compositions having good stability
US6096340A (en) Omeprazole formulation
EP0589981A1 (de) Pantoprazol enthaltende orale darreichungsformen.
MXPA03008340A (es) Calcio de atorvastatina en una forma farmaceutica, su composicion, y formulacion farmaceutica que comprende calcio de atorvastatina.
WO2006070781A1 (ja) 塩基性薬物又はその塩を含有するマトリックス型徐放性製剤およびその製造方法
JPH0768125B2 (ja) 酸不安定化合物の内服用製剤
WO1998001114A1 (en) Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
KR20020002321A (ko) 미감이 차폐된 약제학적 입자
EP2988733B1 (en) Pharmaceutical composition containing crystalline macitentan
JP4127740B2 (ja) 安定化したベンズイミダゾール系化合物含有組成物
PT2468361E (pt) Formulações de vildagliptina
JP4540092B2 (ja) 酸に不安定な生理活性化合物を含有する製剤組成物及びその製法
US20070224260A1 (en) Dosage Form Having Polymorphic Stability
JPH0157090B2 (en:Method)
RU2141825C1 (ru) Способ получения лекарственной формы карбамазепина
CA2920247C (en) Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
WO2020003196A1 (en) Pharmaceutical composition of axitinib
JP2935220B6 (ja) 安定性良好な医薬組成物
US20040105886A1 (en) Divalproex sodium tablets

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20000728